Pharmaceutical

Veeva Announces Research Site Clinical Trial Management System

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors PLEASANTON, Calif., April 1, 2025 /PRNewswire/ -- Veeva…

9 months ago

EVERSANA Joins Veeva AI Partner Program

Program partner to develop GenAI solutions that seamlessly integrate with Veeva applications CHICAGO, April 1, 2025 /PRNewswire/ -- EVERSANA, a…

9 months ago

Policy Reporter by Mercalis and AccessSync Announce Strategic Partnership to Transform Market Access Capabilities

Collaboration integrates comprehensive payer policy intelligence with Access Realization™ solutions to overcome market access complexity for life sciences products MORRISVILLE,…

9 months ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD…

9 months ago

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen…

9 months ago

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®

BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies,…

9 months ago

Updated biographies for board candidates at the upcoming Annual General Meeting

1 April 2025Announcement no. 8 Updated biographies for board candidates at the upcoming Annual General Meeting Copenhagen, Denmark, April 1,…

9 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,…

9 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

9 months ago

Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025

Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II,…

9 months ago